By Owen Tucker-Smith
Shares of TG Therapeutics rose after the company raised its guidance on better-than-expected sales of its multiple sclerosis drug.
Shares were up 7.7% Tuesday to $29.79. The stock is about 18% below its 52-week high of $36.84.
The company said Briumvi, its multiple sclerosis drug, brought in $103.6 million in the fourth quarter and $310 million in 2024. In November, the company said it expected between $300 million and $305 million from the drug for the year.
TG Therapeutics also said it expects total global revenue around $540 million in 2025. Briumvi will bring in $525 million in the U.S., a 69% jump from the drug's 2024 sales.
The company noted that in the coming year, it plans to enroll participants in an ongoing trial testing Briumvi in diseases outside of multiple sclerosis.
"We believe Briumvi is well positioned to continue to grow and provide value to patients and physicians," said Chief Executive Michael Weiss.
Write to Owen Tucker-Smith at owen.tucker-smith@wsj.com
(END) Dow Jones Newswires
January 14, 2025 15:51 ET (20:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。